Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.

A method and a system of detecting, identifying and quantifying an analyte, for example coronavirus, in a specimen comprising, comprising: apportioning the suspended specimen into one or more test samples; optionally adding a reagent to the test samples; and applying an electric field with a first magnitude and with a second magnitude over the test samples for a selected period of time. The second magnitude should be higher than the first magnitude. The method and system further comprises: measuring electrical properties of said one or more test samples in response to said applied electric field for said first magnitude and for said second magnitude over said period of time; identifying characteristics of said electrical properties responses; and determining the presence, the identification and/or the quantity of coronavirus based on the characteristics of said electrical properties responses to said first magnitude and to said second magnitude of the applied electric field.

A method of determining susceptibility to COVID-19 infection comprising the steps of providing a stool sample, and determining an amount of Bifidobacterium, Clostridium, Faecalibacterium, Faecalibacterium prausnitzii, Ruminococcus, and Subdoligranulum in the stool sample. A method of determining susceptibility to COVID-19 infection comprising the steps of providing a stool sample, and determining an amount of Bifidobacterium and Faecalibacterium, in the stool sample. A method of reducing the severity of COVID-19 infection comprising the steps of providing the individual, and administering at least one of the following: Bifidobacterium and or Faecalibacterium. A method of reducing the risk of infection of COVID-19 comprising the steps of providing the individual, and administering Bifidobacterium and or Faecalibacterium. A method of increasing an amount of Bifidobacterium and Faecalibacterium in an individual, the method comprising the steps of providing the individual; and administering one or more of the following: Vitamin C, doxycycline, Zinc, and Ivermectin.

Lateral flow assay (LFA) devices for detecting whether SARS-CoV-2 nucleocapsid protein is present in a sample are provided. Aspects of the LFA devices include: a sample receiving region; a conjugate region downstream from the sample receiving region that includes test particulate labels made up of label particles conjugated to first and second specific binding members that specifically bind to the SARS-CoV-2 nucleocapsid protein; and a detection region downstream from the conjugate region which includes an immobilized capture specific binding member that specifically binds to the SARS-CoV-2 nucleocapsid protein. Also provided are methods of using the LFA devices, as well as readers, systems and kits for use in the same.

An eyewear device that includes a frame and two arms extending distally from the frame with at least one processor included on the frame or the arms and at least two proximity sensors disposed within the frame or arms in a directional manner. The proximity sensors include an infrared signal receiver to receive an infrared emission. The processors execute an operation to warn a person wearing the eyeglasses by emitting a signal selected from a sound, light or vibration when the proximity sensor detects an infrared emission.

Certain embodiments of the invention include recombinant reverse genetic systems for Omicron variant of SARS-CoV-2 virus.

Provided herein are methods, compositions, kits, and systems for the detection of neutralization targets such as neutralizing antibodies.

The present invention relates to a peptide for treatment of the corona virus infection COVID-19 and a use thereof. In order to make the binding to the new epitope of SARS-CoV2 RBD stronger compared to the peptide (P6) simulating the conventionally known binding site between SARS-CoV RBD and ACE2, the peptide of the present invention includes a new portion added with a novel amino acid sequence fundamentally designed for interaction in the dimension of atoms consisting of the amino acids. Suggested in the present invention is a novel design of a peptide having higher binding affinity than conventionally known peptides, wherein an expanded peptide is creatively designed to additionally interact with charged amino acids of D420 and K458, located at the rear side of the known binding boundary between RBD and hACE2. The peptide of the present invention exhibits high possibility as a therapeutic agent for COVID-19.

The present disclosure relates to variants of SARS-CoV-2 nucleocapsid protein, spike protein, and spike protein receptor binding domain (RBD), as well as nucleic acids encoding such variants and methods of use thereof. Such variants are useful in diagnostic test kits and vaccines for SARS-CoV-2.

The present specification provides reagents and methods for a rapid detection of SARS-CoV-2. The assay can be implemented in a point-of-care or laboratory setting.